This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

5 Rocket Stocks to Buy Now


Content on this page requires a newer version of Adobe Flash Player.

Get Adobe Flash player

Biopharma firm Celgene ( CELG) is another stock that's posted some blockbuster performance numbers in 2013; this $66 billion drug maker has seen its shares more than double since the start of the year. But despite that breakneck performance, CELG is well-positioned for more upside before the year is over.

>>5 Stocks Under $10 Set to Soar

Celgene is a biopharmaceutical firm that focuses on cancer and immunology therapies. The firm's drug portfolio includes established niche names such as Revlimid, Thalomid and Vidaza alongside newer offerings such as Pomalyst. Celgene's relatively narrow focus has been a major benefit for the firm -- it doesn't stray too far from its core competency, and as a result, the firm has been able to come up with new indications for existing therapies. Taking Revlimid to Europe should be a major revenue driver for CELG in the next couple of years despite speed bumps in getting approval; already, the drug is closing in on the $4 billion sales level this year in the U.S.

With more than $2 billion in annual free cash flow generation, Celgene currently sports a balance sheet that's net cash positive to the tune of half a billion dollars -- that's in spite of a growth-by-acquisition strategy that's added considerable new drugs to the firm's pipeline in recent years.

With rising analyst sentiment in Celgene this week, we're betting on shares.
3 of 6

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free

Check Out Our Best Services for Investors

Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
AFL $68.74 0.45%
CELG $101.35 0.45%
ECL $115.32 0.01%
TWX $75.55 1.00%
V $77.42 0.45%


Chart of I:DJI
DOW 17,711.90 +60.64 0.34%
S&P 500 2,057.23 +6.11 0.30%
NASDAQ 4,738.7810 +13.1420 0.28%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs